Twenty-four seven
7074
Alpico Holdings
297A
Branding Technology
7067
Estore
4304
Axel Mark
3624
JP Stock MarketDetailed Quotes
4582 SymBio Pharmaceuticals
- 199
- +7+3.65%
20min DelayMarket Closed Dec 27 15:30 JST
9.14BMarket Cap-4.05P/E (Static)
202High194Low466.90KVolume194Open192Pre Close93.05MTurnover47552wk High1.09%Turnover Ratio45.92MShares14652wk Low-92.73EPS TTM8.56BFloat Cap6320Historical HighLossP/E (Static)43.01MShs Float146Historical Low-49.19EPS LYR4.17%Amplitude--Dividend TTM1.41P/B100Lot Size--Div YieldTTM
SymBio Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -50.59%613.94M | -57.98%686.56M | -61.30%597.87M | -44.15%5.59B | -55.95%1.17B | -49.94%1.24B | -36.12%1.63B | -33.30%1.54B | 21.28%10.01B | -1.73%2.65B |
| Cost of revenue | -30.68%165.88M | -60.05%161.4M | -57.96%126.76M | -51.06%1.18B | -54.99%233.84M | -76.67%239.3M | -9.28%404M | -27.84%301.56M | -1.80%2.41B | -45.04%519.53M |
| Gross profit | -55.33%448.07M | -57.30%525.17M | -62.11%471.1M | -41.96%4.41B | -56.18%934.76M | -31.11%1B | -41.78%1.23B | -34.50%1.24B | 31.03%7.6B | 21.60%2.13B |
| Operating expense | 22.89%1.52B | 8.05%1.44B | 7.20%1.28B | -7.34%5.22B | -16.79%1.46B | -0.26%1.24B | 6.54%1.33B | -14.18%1.19B | 17.81%5.64B | 51.27%1.76B |
| Operating profit | -358.96%-1.07B | -803.94%-912.79M | -1,674.18%-806.7M | -141.34%-811.67M | -241.01%-528.46M | -207.90%-233.47M | -111.70%-100.98M | -89.94%51.25M | 93.27%1.96B | -36.67%374.77M |
| Net non-operating interest income (expenses) | 484.79%8.4M | -146.73%-1.55M | -1,229.85%-2.67M | 101.08%494K | 1,519.03%3.51M | -776.71%-2.18M | 98.61%-627K | 27.17%-201K | -2,407.89%-45.77M | 23.53%-247K |
| Non-operating interest income | 7,684.75%9.19M | 180,614.29%12.65M | 442.25%770K | 12,116.33%11.97M | 390,066.67%11.71M | 78.79%118K | 0.00%7K | 545.45%142K | -21.60%98K | -57.14%3K |
| Total other finance cost | -65.84%786K | 2,139.27%14.2M | 903.79%3.44M | -74.98%11.48M | 3,180.00%8.2M | 630.48%2.3M | -98.59%634K | 15.10%343K | 2,252.15%45.87M | -24.24%250K |
| Net investment income | -722.02%-229.87M | 29.09%164.73M | 2,720.79%84.4M | -14.01%117.11M | 75.87%-50.45M | -79.14%36.96M | -15.56%127.61M | -82.41%2.99M | 873.44%136.18M | -16,552.24%-209.11M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 71.02%-20.6M | -94.98%4.44M | -2,070.43%-49.18M | -541.26%-467.13M | -12,174,900.00%-487M | -71.1M | -16.42%88.48M | 2.5M | 53,365.15%105.86M | -4K |
| Less:Other special charges | 53.13%-2.08M | ---- | ---- | 11.71%-93.47M | 48,725.00%1.95M | ---4.44M | ---88.48M | ---2.5M | -53,365.15%-105.86M | --4K |
| Less:Write off | -69.97%22.68M | --7.77M | --49.18M | --560.59M | --485.05M | --75.54M | --0 | --0 | --0 | --0 |
| Other non-operating income (expenses) | 159.91%14.75M | -205.35%-4.51M | 59.94%-2.29M | 36.23%-34.19M | 73.39%-2.38M | -941.81%-24.62M | -444.65%-1.48M | 87.93%-5.71M | -1,274.55%-53.62M | -48.82%-8.95M |
| Income before tax | -341.15%-1.3B | -763.36%-749.66M | -1,627.75%-776.45M | -156.75%-1.2B | -780.57%-1.06B | -174.31%-294.43M | -89.49%113.01M | -89.38%50.82M | 110.35%2.11B | -73.33%156.46M |
| Income tax | -98.84%4.82M | -92.76%14.28M | -97.95%950K | -17.22%767.43M | -79.49%109.31M | 905.55%414.44M | 51.69%197.32M | -85.30%46.37M | 189.93%927.04M | 147.56%532.97M |
| Net income | -83.91%-1.3B | -806.15%-763.94M | -17,546.07%-777.4M | -266.45%-1.96B | -211.84%-1.17B | -258.35%-708.86M | -108.92%-84.31M | -97.27%4.46M | -41.97%1.18B | -122.05%-376.51M |
| Net income continuous operations | -83.91%-1.3B | -806.15%-763.94M | -17,546.07%-777.4M | -266.45%-1.96B | -211.84%-1.17B | -258.35%-708.86M | -108.92%-84.31M | -97.27%4.46M | -41.97%1.18B | -122.05%-376.51M |
| Noncontrolling interests | 0 | 0 | 0 | 0 | ||||||
| Net income attributable to the company | -83.91%-1.3B | -806.17%-763.94M | -17,549.99%-777.4M | -266.45%-1.96B | -211.84%-1.17B | -258.35%-708.86M | -108.92%-84.31M | -97.27%4.46M | -41.97%1.18B | -122.05%-376.51M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -83.91%-1.3B | -806.17%-763.94M | -17,549.99%-777.4M | -266.45%-1.96B | -211.84%-1.17B | -258.35%-708.86M | -108.92%-84.31M | -97.27%4.46M | -41.97%1.18B | -122.05%-376.51M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -60.49%-28.68 | -684.98%-16.72 | -16,490.91%-18.03 | -262.88%-49.19 | -198.98%-29.3 | -258.28%-17.87 | -108.71%-2.13 | -97.41%0.11 | -43.06%30.2 | -121.99%-9.8 |
| Diluted earnings per share | -60.49%-28.68 | -684.98%-16.72 | -16,490.91%-18.03 | -265.23%-49.19 | -198.98%-29.3 | -260.85%-17.87 | -108.82%-2.13 | -97.37%0.11 | -43.10%29.77 | -122.29%-9.8 |
| Dividend per share | ||||||||||
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |